These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11283519)

  • 1. Lupus nephritis: lessons from experimental animal models.
    Peutz-Kootstra CJ; de Heer E; Hoedemaeker PJ; Abrass CK; Bruijn JA
    J Lab Clin Med; 2001 Apr; 137(4):244-60. PubMed ID: 11283519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of autoimmune (lupus-like) glomerulonephritis in murine models.
    Hicks J; Bullard DC
    Ultrastruct Pathol; 2006; 30(5):345-59. PubMed ID: 17090514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice.
    Miyazaki T; Ono M; Qu WM; Zhang MC; Mori S; Nakatsuru S; Nakamura Y; Sawasaki T; Endo Y; Nose M
    Eur J Immunol; 2005 May; 35(5):1510-20. PubMed ID: 15832294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA.
    Qiao B; Wu J; Chu YW; Wang Y; Wang DP; Wu HS; Xiong SD
    Rheumatology (Oxford); 2005 Sep; 44(9):1108-14. PubMed ID: 15840592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis.
    Du Y; Fu Y; Mohan C
    Arch Immunol Ther Exp (Warsz); 2008; 56(1):31-40. PubMed ID: 18250969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of antibodies and B cells in the pathogenesis of lupus nephritis.
    Shlomchik MJ; Madaio MP
    Springer Semin Immunopathol; 2003 May; 24(4):363-75. PubMed ID: 12778333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance.
    Sinico RA; Radice A; Ikehata M; Giammarresi G; Corace C; Arrigo G; Bollini B; Li Vecchi M
    Ann N Y Acad Sci; 2005 Jun; 1050():193-200. PubMed ID: 16014534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.
    Savarese E; Steinberg C; Pawar RD; Reindl W; Akira S; Anders HJ; Krug A
    Arthritis Rheum; 2008 Apr; 58(4):1107-15. PubMed ID: 18383384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
    Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
    Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis.
    Fu Y; Du Y; Mohan C
    Clin Immunol; 2007 Aug; 124(2):109-18. PubMed ID: 17640604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1/Th2 balance of SLE patients with lupus nephritis.
    Nakashima H; Akahoshi M; Masutani K
    Rinsho Byori; 2006 Jul; 54(7):706-13. PubMed ID: 16913661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.
    Lajaunias F; Ida A; Kikuchi S; Fossati-Jimack L; Martinez-Soria E; Moll T; Law CL; Izui S
    Arthritis Rheum; 2003 Jun; 48(6):1612-21. PubMed ID: 12794829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of lupus nephritis: an update.
    Tang S; Lui SL; Lai KN
    Nephrology (Carlton); 2005 Apr; 10(2):174-9. PubMed ID: 15877678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental use of murine lupus models.
    Peng SL
    Methods Mol Med; 2004; 102():227-72. PubMed ID: 15286389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
    Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
    Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell apoptosis accelerates the onset of murine lupus.
    Trébéden-Nègre H; Weill B; Fournier C; Batteux F
    Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S; Wilde B; Patschan S; Dürig J; Specker C; Philipp T; Kribben A; Witzke O
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis.
    Vielhauer V; Anders HJ; Schlöndorff D
    Semin Nephrol; 2007 Jan; 27(1):81-97. PubMed ID: 17336691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.